Disease Elimination Program, Burnet Institute, Melbourne, Victoria, Australia.
Department of Infectious Diseases, Alfred Health and Monash University, Melbourne, Victoria, Australia.
JAMA. 2019 Apr 9;321(14):1380-1390. doi: 10.1001/jama.2019.2947.
Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).
To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following PrEP commencement.
DESIGN, SETTING, AND PARTICIPANTS: The Pre-exposure Prophylaxis Expanded (PrEPX) Study, a multisite, open-label intervention study, was nested within the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) clinic network. A total of 4275 participants were enrolled (July 26, 2016-April 1, 2018) in Victoria, Australia. Of these, 2981 enrolled at 5 ACCESS clinics (3 primary care, 1 sexual health, and 1 community-based HIV rapid testing service), had at least 1 follow-up visit, and were monitored until April 30, 2018.
Upon enrollment, participants received daily oral tenofovir disoproxil fumurate and emtricitabine for HIV PrEP, quarterly HIV and STI testing, and clinical monitoring.
The primary outcome was incidence of chlamydia, gonorrhea, or syphilis. Incidence rates and hazard ratios describing behavioral risk factors of STI diagnosis were calculated. Incidence rate ratios (IRRs), adjusted for change in testing frequency, described changes in STI incidence from 1-year preenrollment to study follow-up among participants with preenrollment testing data (n = 1378).
Among the 2981 individuals (median age, 34 years [interquartile range, 28-42]), 98.5% identified as gay or bisexual males, 29% used PrEP prior to enrollment, 89 (3%) withdrew and were censored at date of withdrawal, leaving 2892 (97.0%) enrolled at final follow-up. During a mean follow-up of 1.1 years (3185.0 person-years), 2928 STIs were diagnosed among 1427 (48%) participants (1434 chlamydia, 1242 gonorrhea, 252 syphilis). STI incidence was 91.9 per 100 person-years, with 736 participants (25%) accounting for 2237 (76%) of all STIs. Among 2058 participants with complete data for multivariable analysis, younger age, greater partner number, and group sex were associated with greater STI risk, but condom use was not. Among 1378 participants with preenrollment testing data, STI incidence increased from 69.5 per 100 person-years prior to enrollment to 98.4 per 100 person-years during follow-up (IRR, 1.41 [95% CI, 1.29-1.56]). After adjusting for testing frequency, the increase in incidence from 1 year preenrollment to follow-up was significant for any STI (adjusted IRR, 1.12 [95% CI, 1.02-1.23]) and for chlamydia (adjusted IRR, 1.17 [95% CI, 1.04-1.33]).
Among gay and bisexual men using PrEP, STIs were highly concentrated among a subset, and receipt of PrEP after study enrollment was associated with an increased incidence of STIs compared with preenrollment. These findings highlight the importance of frequent STI testing among gay and bisexual men using PrEP.
越来越多的证据表明,在开始使用艾滋病毒暴露前预防 (PrEP) 后,男同性恋和双性恋者感染细菌性性传播感染 (STI) 的风险增加。
描述在一个主要由男同性恋和双性恋者组成的接受 PrEP 的队列中,性传播感染 (STI) 的发病率和行为风险因素,并探讨 PrEP 开始后 STI 发病率的变化。
设计、地点和参与者:暴露前预防扩展 (PrEPX) 研究是一项多地点、开放性干预研究,嵌套在澳大利亚合作协调强化监测 (ACCESS) 诊所网络中。共有 4275 名参与者 (2016 年 7 月 26 日至 2018 年 4 月 1 日) 在澳大利亚维多利亚州入组。其中,5 家 ACCESS 诊所 (3 家初级保健诊所、1 家性健康诊所和 1 家社区 HIV 快速检测服务) 有 2981 名参与者至少有 1 次随访,随访至 2018 年 4 月 30 日。
入组时,参与者每天口服替诺福韦二吡呋酯和恩曲他滨进行 HIV PrEP,每季度进行 HIV 和 STI 检测,并进行临床监测。
主要结果是衣原体、淋病或梅毒的发病率。计算了描述 STI 诊断行为风险因素的发病率和风险比。调整了检测频率的变化,描述了在有入组前检测数据的参与者中,从入组前 1 年到研究随访期间 STI 发病率的变化(n=1378)。
在 2981 名个体中(中位数年龄,34 岁[四分位距,28-42]),98.5%的人被确定为男同性恋或双性恋男性,29%的人在入组前使用 PrEP,89 人(3%)退出并在退出时被删失,2892 人(97.0%)在最后一次随访时入组。在平均 1.1 年(3185.0 人年)的随访期间,1427 名参与者中有 2928 名诊断出 STI(1434 例衣原体、1242 例淋病、252 例梅毒)。STI 的发病率为 91.9/100 人年,736 名参与者(25%)占所有 STI 的 2237 例(76%)。在 2058 名接受多变量分析完整数据的参与者中,年龄较小、伴侣数量较多和群体性行为与更大的 STI 风险相关,但使用避孕套则不然。在 1378 名有入组前检测数据的参与者中,STI 的发病率从入组前的 69.5/100 人年增加到随访期间的 98.4/100 人年(IRR,1.41[95%CI,1.29-1.56])。在调整检测频率后,从入组前 1 年到随访期间,任何 STI 的发病率增加均有统计学意义(调整后的 IRR,1.12[95%CI,1.02-1.23]),以及衣原体的发病率增加也有统计学意义(调整后的 IRR,1.17[95%CI,1.04-1.33])。
在使用 PrEP 的男同性恋和双性恋者中,STI 高度集中在一部分人群中,与入组前相比,在入组后接受 PrEP 与 STI 发病率增加有关。这些发现强调了男同性恋和双性恋者使用 PrEP 时进行频繁的 STI 检测的重要性。